July 2026
Longevity research from July 2026, curated and analyzed through the EDGE Framework.
Lecanemab Three-Year Data and Blood Biomarkers Transform Alzheimer's Detection
Eisai will present data on lecanemab (LEQEMBI) including subcutaneous formulation efficacy and three-year outcomes, alongside new anti-tau antibody research and blood-based biomarker diagnostics at the 2026 Alzheimer's Association conference. These presentations reflect a shift toward earlier detection and intervention before cognitive decline becomes irreversible.
One-Time Gene Therapy Reduces Tau Protein in Alzheimer's Disease
Voyager Therapeutics has obtained FDA clearance to initiate clinical trials for VY1706, a single-administration gene therapy targeting tau protein in early Alzheimer's disease. Preclinical data demonstrated tau reductions up to 75% in relevant brain regions with acceptable tolerability, positioning this approach as a potential disease-modifying intervention for neurodegeneration.
Gene therapy for aging advances to animal trials
Genflow Biosciences secured overwhelming shareholder approval for board leadership and capital authorization to advance its gene therapy pipeline targeting age-related diseases. The company is progressing GF-1002, its lead therapeutic candidate, through preclinical validation and early clinical evaluation in animal models with plans for human trials in metabolic disease.
POZ Platform Delivery Advances Parkinson's Clinical Development
Serina Therapeutics and Gannet BioChem have partnered to develop SER-252, an investigational Parkinson's therapy that recently received FDA clearance to enter clinical trials. The collaboration leverages Serina's POZ Platform delivery technology with Gannet's manufacturing expertise to advance a neurodegenerative treatment toward human studies.
Muscle-bone link: shared pathways in sarcopenia and osteoporosis
Sarcopenia and osteoporosis function as reciprocal risk factors sharing genetic architecture, circulating biomarkers, and metabolic pathways. Muscle strength, lean mass, and bone density each independently reduce risk of the other condition, with plasma proteins and metabolites acting as mechanistic mediators of this muscle-bone relationship.